The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial

被引：1
|
作者：
Huang, Jingjing [1 ]
Yu, Yimin [1 ]
Jiang, Yi [2 ]
Chen, Wu [2 ]
Li, Yan [1 ]
Shen, Yifeng [1 ]
Zheng, Qingshan [3 ]
Li, Huafang [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, 600 Wan Ping Nan Rd, Shanghai 200030, Peoples R China
[2] Su Zhou YiHua Biotechnol Co Ltd, Suzhou, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China
来源：
TRIALS | 2021年 / 22卷 / 01期
关键词：
Depression; Anyu Peibo Capsule; Randomized controlled trials; MEDICINAL-PLANTS; GLOBAL IMPRESSION; SCALE; ANTIDEPRESSANT;
D O I：
10.1186/s13063-021-05550-9
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background: Major depressive disorder is the second leading cause of years lost to disability worldwide. Anyu Peibo Capsule has been shown to be effective and safe in phase II trials. Methods: This clinical study is a multi-center, randomized, double-blinded, placebo-controlled, parallel-group, phase III trial of Anyu Peibo Capsule in China. The aim is to test whether the administration of Anyu Peibo Capsule compared to placebo improves clinical outcomes in adults (aged 18 to 65 years) with MDD. Patients will receive an 8-week treatment of Anyu Peibo Capsule 1.6 g per day or placebo. The primary outcome will be the change from baseline in the total score for the Montgomery-Asberg Depression Rating Scale at the end of the 8-week treatment. Discussion: The trial aims to provide pivotal evidence for the efficacy and safety of Anyu Peibo Capsule in patients with major depressive disorder.
引用
收藏
页数：9
相关论文
共 50 条
  • [11] Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
    Hobart, Mary
    Skuban, Aleksandar
    Zhang, Peter
    Josiassen, Mette Krog
    Hefting, Nanco
    Augustine, Carole
    Brewer, Claudette
    Sanchez, Raymond
    McQuade, Robert D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (04) : 633 - 642
  • [12] Efficacy and Safety of Curcumin in Major Depressive Disorder: A Randomized Controlled Trial
    Sanmukhani, Jayesh
    Satodia, Vimal
    Trivedi, Jaladhi
    Patel, Tejas
    Tiwari, Deepak
    Panchal, Bharat
    Goel, Ajay
    Tripathi, Chandra Bhanu
    PHYTOTHERAPY RESEARCH, 2014, 28 (04) : 579 - 585
  • [13] Rosemary as an adjunctive treatment in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial
    Azizi, Saeed
    Mohamadi, Neda
    Sharififar, Fariba
    Dehghannoudeh, Gholamreza
    Jahanbakhsh, Farzaneh
    Dabaghzadeh, Fatemeh
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2022, 49
  • [14] A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical
    Gaynor, Paula J.
    Gopal, Murali
    Zheng, Wei
    Martinez, James M.
    Robinson, Michael J.
    Marangell, Lauren B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (10) : 1849 - 1858
  • [15] Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial
    Hoobehfekr, Saba
    Moghaddam, Hossein Sanjari
    Shalbafan, Mohammadreza
    Hashemi, Maryam Ghazizadeh
    Pirmoradi, Mohammad Mehdi
    Sakenian, Amirhossein
    Poopak, Amirhossein
    Kashefinejad, Shayan
    Yarahmadi, Masoomeh
    Akhondzadeh, Shahin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (02) : 57 - 62
  • [16] The efficacy and safety of sulforaphane as an adjuvant in the treatment of bipolar depressive disorder Study protocol for a randomized, double-blinded, placebo-controlled, parallel-group clinical trial
    Wu, Congchong
    Chen, Xingyang
    Lai, Jianbo
    Xu, Yi
    Hu, Shaohua
    MEDICINE, 2020, 99 (26) : E20981
  • [17] A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
    Sinha, Shubhadeep
    Chary, Sreenivasa
    Thakur, Pankaj
    Talluri, Leela
    Reddy, Mohan
    Verma, Kamal K.
    Saha, Pradeep
    Gupta, Vijaya B.
    Ramaiah, Kaja A.
    Khanum, Siquafa Z.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (07)
  • [18] Reducing depressive symptomatology with a smartphone app: study protocol for a randomized, placebo-controlled trial
    Giosan, Cezar
    Cobeanu, Oana
    Mogoase, Cristina
    Szentagotai, Aurora
    Muresan, Vlad
    Boian, Rares
    TRIALS, 2017, 18
  • [19] Efficacy and safety of add-on sarcosine in patients with major depressive disorder: A randomized controlled trial
    Padhan, Milan
    Mohapatra, Debadatta
    Mishra, Biswa Ranjan
    Maiti, Rituparna
    Jena, Monalisa
    JOURNAL OF PSYCHIATRIC RESEARCH, 2024, 178 : 298 - 304
  • [20] Evaluation of the efficacy and safety of Yukwool-tang for major depressive disorder in women: A randomized, double blinded, placebo-controlled, parallel trial
    Seo, Young Kyung
    Choi, Sunyoung
    Choi, Youngeun
    Choi, Sungmin
    Kwon, Ojin
    Kim, Hyungjun
    Jung, In Chul
    MEDICINE, 2024, 103 (21) : E38208
12345